Based on the Karyopharm Therapeutics Inc stock forecast from 4 analysts, the average analyst target price for Karyopharm Therapeutics Inc is USD 5.00 over the next 12 months. Karyopharm Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Karyopharm Therapeutics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Karyopharm Therapeutics Inc’s stock price was USD 1.53. Karyopharm Therapeutics Inc’s stock price has changed by +31.90% over the past week, +0.33% over the past month and -51.43% over the last year.
No recent analyst target price found for Karyopharm Therapeutics Inc
No recent average analyst rating found for Karyopharm Therapeutics Inc
Company Overview Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor...Read More
Adjusted Closing Price for Karyopharm Therapeutics Inc (KPTI)
Loading...
Unadjusted Closing Price for Karyopharm Therapeutics Inc (KPTI)
Loading...
Compare Performance of Karyopharm Therapeutics Inc Shares
Symbol
Capital Gain
Dividend Return
Total Return
Loading...
Loading...
Technical Indicators for KPTI
Assets
Top Holdings
N/A
Top Sectors
Top Regions
Stocks Similar To Karyopharm Therapeutics Inc (Sector: Biotechnology )
Symbol
Name
Price(Change)
Market Cap
Price / Earning Ratio
EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc
-1.31 (-0.32%)
USD90.49B
26.38
17.57
ETFs Containing KPTI
Symbol
Name
KPTI's Weight
Expense Ratio
Price(Change)
Market Cap
no data
Frequently Asked Questions About Karyopharm Therapeutics Inc (KPTI) Stock
Based on ratings from 4 analysts Karyopharm Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on KPTI's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for KPTI is USD 5.00 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on KPTI's stock to indicate if its overvalued.
The last closing price of KPTI's stock was USD 1.53.
The most recent market capitalization for KPTI is USD 0.10B.
Based on targets from 4 analysts, the average taret price for KPTI is projected at USD 5.00 over the next 12 months. This means that KPTI's stock price may go up by +226.80% over the next 12 months.
We can't find any ETFs which contains Karyopharm Therapeutics Inc's stock.
As per our most recent records Karyopharm Therapeutics Inc has 385 Employees.
Karyopharm Therapeutics Inc's registered address is 85 Wells Avenue, Newton, MA, United States, 02459. You can get more information about it from Karyopharm Therapeutics Inc's website at https://www.karyopharm.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
The highest analyst price target is $8.00 ,the lowest forecast is $3.00. The average price target represents 412.82% Increase from the current price of $1.17. Karyopharm Therapeutics's analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
Based on analysts offering 12 month price targets for KPTI in the last 3 months. The average price target is $5.8 with a high estimate of $8 and a low estimate of $3.
According to our current KPTI stock forecast, the value of Karyopharm Therapeutics shares will drop by -3.20% and reach $ 1.055075 per share by April 30, 2024. Per our technical indicators, the current sentiment is Bearish while the Fear & Greed Index is showing 39 (Fear).
Largest shareholders include BlackRock Inc., Vanguard Group Inc, Avidity Partners Management LP, Palo Alto Investors LP, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Citadel Advisors Llc, IWM - iShares Russell 2000 ETF, Geode Capital Management, Llc, Gsa Capital Partners Llp, and VEXPX - VANGUARD ...
Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer and other major diseases.
Total revenue: Total revenue for the fourth quarter of 2023 was $33.7 million, compared to $33.6 million for the fourth quarter of 2022. Total revenue for the year ended December 31, 2023 was $146.0 million, compared to $157.1 million for the year ended December 31, 2022.
The Ultra price prediction for 2025 is currently between $ 0.167550 on the lower end and $ 0.675683 on the high end. Compared to today's price, Ultra could gain 271.68% by 2025 if UOS reaches the upper price target.
The forecasts range from a low of $13.13 to a high of $75.6. A stock's price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Given its current growth rate, $FGHT can reach a value between $1 and $1.5 by the end of 2030. The platform's focus on healthy habits, its partnerships with notable figures in the fitness industry, and its limited token supply all contribute to its potential for long-term growth and success.
For 2024, Fastly guided for revenue between $555 million and $565 million as well adjusted loss per-share between 6 cents and 12 cents. Analysts polled by FactSet expected $584.7 million in revenue and an adjusted loss of 4 cents a share.
According to the latest long-term forecast, QuantumScape price will hit $9 by the end of 2025 and then $10 by the end of 2026. QuantumScape will rise to $12 within the year of 2027, $15 in 2029, $17 in 2031 and $20 in 2035.
As per technical data, the minimum share price target in 2024 for METROPOLIS is expected to be ₹1892.1 and the maximum price target for 2024 will be ₹2320.
Largest shareholders include BlackRock Inc., Vanguard Group Inc, Avidity Partners Management LP, Palo Alto Investors LP, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Citadel Advisors Llc, IWM - iShares Russell 2000 ETF, Geode Capital Management, Llc, Gsa Capital Partners Llp, and VEXPX - VANGUARD ...
Net product revenue: Net product revenue for the fourth quarter of 2023 was $25.1 million, compared to $31.1 million for the fourth quarter of 2022. Net product revenue for the year ended December 31, 2023 was $112.0 million, compared to $120.4 million for the year ended December 31, 2022.
Address: Apt. 814 34339 Sauer Islands, Hirtheville, GA 02446-8771
Phone: +337636892828
Job: Lead Hospitality Designer
Hobby: Urban exploration, Tai chi, Lockpicking, Fashion, Gunsmithing, Pottery, Geocaching
Introduction: My name is Ray Christiansen, I am a fair, good, cute, gentle, vast, glamorous, excited person who loves writing and wants to share my knowledge and understanding with you.
We notice you're using an ad blocker
Without advertising income, we can't keep making this site awesome for you.
